ProCE Banner Activity

Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC

Slideset

The role of risk assessment and biomarkers in guiding optimal therapy selection and individualized strategies for adjuvant therapy including CDK4/6 inhibitors in patients with HR-positive HER2-negative early breast cancer are discussed.

Released: October 04, 2024

Expiration: October 03, 2025

Share

Faculty

Jamie L. Carroll

Jamie L. Carroll, APRN, CNP, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner